Fast-growing cancer could be slowed by common blood pressure drug, research shows

This post was originally published on this site.

Scientists studying an existingblood pressure drugcalled hydralazine accidentally discovered that it could potentially fight cancer.

Hydralazine has been used to treat high blood pressure since the 1950s, but until now it’s been unclear exactly how it works.

“It came from a ‘pre-target’ era of drug discovery, when researchers relied on what they saw in patients first and only later tried to explain the biology behind it,” Kyosuke Shishikura, a physician-scientist at the University of Pennsylvania who was involved in the study, said in a press release from the university.

ALZHEIMER’S PILL COULD REDUCE BRAIN DECLINE IN SOME HIGH-RISK PATIENTS, TRIAL SUGGESTS

Shishikura and a wider research team uncovered that hydralazine directly targets a small but crucial enzyme called 2-aminoethanethiol dioxygenase (ADO).

This enzyme acts like a cellular oxygen sensor, helping cells survive when oxygen levels are low.This can help enable fast-growing tumors like glioblastoma, an aggressive form ofbrain cancerthat resists treatment and almost always comes back.

Hydralazine has been around since the 1950s and is traditionally used to treat high blood pressure, but researchers didn’t understand exactly how it worked before now.(iStock)

In fast-growing cancers like glioblastoma, the tumor cells multiply so quickly that their blood supply can’t keep up.That means parts of the tumor don’t get enough oxygen.

Typical cells die in low-oxygen environments, buttumor cellsswitch on special survival systems that help them keep dividing even when oxygen is scarce.One of those systems involves the ADO enzyme, studies show.

NEW VITAMIN COMPOUND SHOWS PROMISE FOR REVERSING ALZHEIMER’S DAMAGE TO THE BRAIN

“ADO is like an alarm bell that rings the moment oxygen starts to fall,” Megan Matthews, an assistant professor in Penn’s Department of Chemistry and a researcher in the study, stated in the same press release.

The team used several advanced techniques — including X-ray crystallography, which analyzes the structure of molecules — to determine how hydralazine binds to ADO.

Man holding the medicine bottle in one hand and pill in other

Hydralazine binds to the enzyme ADO and makes it stop working.This shuts down the cell’s oxygen response system, and in the case of cancer cells, forces them to stop dividing.(iStock)

They discovered that hydralazine silences that alarm by binding to ADO and making it stop working.This shuts down the cell’s oxygen response system — and, in the case ofcancer cells, forces them to stop dividing.

onelink.me/xLDS?pid=AppArticleLink&af_web_dp=https%3A%2F%2Fwww.

To test this discovery, the team treated human glioblastoma cells with hydralazine in the lab.After three days, they discovered that the cells had stopped multiplying and became larger and flatter.The cells had entered a kind of permanent “sleep mode” known as “senescence,” the researchers noted.

surgery and chemotherapy, according to Memorial Sloan Kettering Cancer Center.

MRI Brain Scan of head and skull with hand pointing

While other cells die when deprived of oxygen, cancer cells continue to adapt and grow due to the ADO enzyme.(iStock)

Because hydralazine is already FDA-approved, researchers hope it could be repurposed forcancer therapymuch faster than a brand-new drug.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

The experiments so far have only been done with cell cultures, not yet in animals or humans, the researchers noted.The next step will beto testwhether ADO can be blocked safely and effectively in living systems.

Khloe Quill is a

Chimpanzee escapes from Indianapolis Zoo enclosure, triggering emergency lockdown

Gut imbalance may be driving America’s food allergy epidemic, experts warn